Medical Device Manufacturing / Nephrology / Dialysis Technology
Strategic Profile
The company is positioned for faster recurring revenue growth through rapid Tablo adoption and strategic partnerships, with demographic trends and expanding home care markets offering lasting tailwinds for long-term profitability. The business model leverages recurring revenue streams and strong customer retention.
Cyborg Score Rationale
Outset operates in a high-growth medical technology sector with innovative products and strategic partnerships. However, the company faces near-term profitability challenges with recent revenue decline and significant operating losses, combined with elevated stock volatility.
Top Insights
2024 revenue was $113.69 million, down 12.8% year-over-year
Average analyst rating is "Strong Buy" with 12-month price target of $14.00, implying 178% upside from recent levels
Recent strategic collaboration announced with Northwest Kidney Centers, a pioneering home hemodialysis program operator
Secured $100 million term loan from Perceptive Advisors with option for $25 million additional funding
Named Competitors
Hemodialysis Systems — Large-scale dialysis treatment provider and equipment operator
Renal Care Solutions — Global dialysis equipment and treatment provider
Home Dialysis Equipment — Peritoneal and hemodialysis equipment provider
Recent Developments
(January 2026) Presented at 44th Annual J.P. Morgan Healthcare Conference
(January 2026) Announced strategic initiatives to reduce dialysis cost and complexity
(September 2025) Established collaboration with Northwest Kidney Centers for home hemodialysis program
(July 2025) Raised 2025 revenue guidance to $122-126 million range
Open the full interactive Outset Medical, Inc. report
Strategic research, analyst-debate audio, full Cyborg Score breakdown across 11 dimensions, and saved-company audio playlists.